Clinical Trial Update: Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 dose-ranging study evaluated pixantrone in the FND-R regimen for indolent non-Hodgkin lymphoma; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma
• Lymphoma Low-grade
• Lymphoma Mixed-cell Follicular
• Lymphoma Small Cleaved-cell Follicular
• Lymphoma Small Lymphocytic

Drugs mentioned

• Pixantrone (pixantrone)

Snippet

Sponsor: CTI BioPharma | Conditions: Lymphoma, Low-Grade, Lymphoma, Small Lymphocytic | Phase 1 | Status: COMPLETED